model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Claude-4.5-Sonnet,protocolSection.identificationModule.nctId,FN,FN,NCT04864691,,False,0.0,,NCTId,protocolSection.identificationModule.nctId,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.briefTitle,FN,FN,Endovascular Recanalization and Standard Medical Management for Symptomatic Nonacute Intracranial Artery Occlusion Trial,,False,0.0,,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.officialTitle,FN,FN,"Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical University",,False,0.0,,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.briefSummary,TP,TP,"Background The management of patients with symptomatic nonacute intracranial artery occlusion (sNA-ICAO), which is a special subset with high morbidity and a high probability of recurrent serious ischemic events despite standard medical therapy (SMT), has been clinically challenging. Some small-sample clinical studies have also discussed endovascular recanalization for sNA-ICAO; however, there is currently a lack of evidence from multicenter, prospective, large-sample cohort trials. The aim of our present study was to evaluate the technical feasibility and safety of endovascular recanalization for sNA-ICAO.

Methods and analysis: Our group is currently undertaking a multisite, nonrandomized cohort, prospective registry study enrolling consecutive patients presenting with sNA-ICAO at 15 centers in China between May 1, 2020, and April 30, 2023. A cohort of patients who received SMT and a cohort of similar patients who received ER plus SMT were constructed and followed up for 2 years. The primary outcome is the composite of stroke/TIA within 2 years following enrollment and stroke/TIA ipsilateral to the target vessel. The secondary efficacy outcome includes the following two parts: 1) the incidence of stroke/TIA ipsilateral to the target vessel within 30 days and 90 days in both groups; 2) the all-cause mortality, mRS score, NIHSS score and cognitive function at 30 days, 90 days, 8 months, 12 months and 24 months for both groups, including the MRI, CTA/MRA, CTP or MRP results in patients with internal carotid artery or middle cerebral artery occlusion as well as CTA in patients with basilar or vertebral artery occlusion at 90 days, 12 months and 24 months. Descriptive statistics and linear/logistic multiple regression models will be generated. Clinical relevance will be measured as relative risk reduction, absolute risk reduction and the number needed to treat.

Ethics and dissemination This study protocol was reviewed and approved primarily by Beijing Tiantan Hospital, the Capital Medical University Medical Ethics Committee, and the institutional review boards of all partner sites. The study is being externally monitored, and the results will be published in open-access peer-reviewed scientific journals and presented to academic and policy stakeholders.","The management of patients with symptomatic non-acute intracranial artery occlusion (sNA-ICAO), which is a special subset with high morbidity and a high probability of recurrent serious ischemic events despite standard medical therapy (SMT), has been clinically challenging. A number of small-sample clinical studies have also discussed endovascular recanalization (ER) for sNA-ICAO; however, there is currently a lack of evidence from multicenter, prospective, large-sample cohort trials. The purpose of this study is to evaluate the technical feasibility and safety of endovascular recanalization for symptomatic non-acute intracranial artery occlusion. This is a multisite, non-randomized cohort, prospective registry study enrolling consecutive patients presenting with sNA-ICAO at 15 centers in China between January 1, 2020 and December 31, 2022. A cohort of patients who received SMT and a cohort of similar patients who received ER plus SMT will be constructed and followed up for 2 years.",True,0.98,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.detailedDescription,EV,EV,,"Large intracranial artery occlusion is a major cause of stroke and is associated with a high risk of stroke recurrence and poor stroke outcome, especially in China. For symptomatic non-acute intracranial artery occlusion (sNA-ICAO) (within 24 h to 6 months), some patients continue to be symptomatic despite standard medical therapy (SMT). Extracranial-intracranial (EC-IC) artery bypass surgery fails to show benefits in preventing ischemic attacks or ischemic stroke when performed for sNA-ICAO. The optimal treatment for patients with sNA-ICAO disease remains undefined. Currently, SMT, including an antiplatelet regimen and risk factor management, has been used to treat patients with sNA-ICAO disease. Unfortunately, the natural course of this condition shows that these patients often experience recurrent symptoms despite SMT. Recently, a series of small-sample clinical studies have reported that endovascular recanalization (ER) is feasible for sNA-ICAO. However, most of the previous studies are based on small-sample, single-center retrospective analyses, and there is no high-level evidence from large multicenter samples or prospective studies to indicate the effectiveness and safety of ER for sNA-ICAO.

This study is a multicenter, prospective registry, non-randomized cohort study sponsored by professor Feng Gao of Beijing Tiantan hospital to assess patients affected by sNA-ICAO undergoing ER and SMT. Fifteen centers across China will participate in the study and provide data. Patients with imaging (MRA/CTA/DSA) and clinical diagnosis of sNA-ICAO will be included. Based on the patient's previous history, imaging features of the lesion and the attitudes of the patient and family members, the local investigative team in each center will determine whether to give SMT plus ER or SMT alone.

Standard Medical Therapy (SMT): Patients in SMT group will take aspirin (100 mg/day) and clopidogrel (75 mg/day) for 90 days followed by lifelong aspirin or clopidogrel monotherapy thereafter. Risk factors including systolic blood pressure and LDL cholesterol will be controlled according to protocols. A lifestyle modification program, INTERVENT, will be provided to each patient.

Endovascular Recanalization (ER) Protocol: A dual antiplatelet regimen with acetylsalicylic acid (100 mg) and clopidogrel (75 mg) is started at least 3 days before the procedure. All procedures are performed under general anesthesia by an experienced interventional neuroradiologist. The procedure involves passage of microcatheter through the occluded segment, balloon dilation, and stent deployment if necessary. Successful revascularization is defined as a modified TICI grade 2b or 3 and residual stenosis <50%. For patients with ICA or MCA M1 segment occlusion, ipsilateral hypoperfusion should be confirmed by CTP or MRI perfusion imaging prior to enrollment.

The primary outcome is any stroke from enrollment to 2 years of follow-up. The secondary outcomes are all-cause mortality, mRS score, NIHSS score and cognitive function from enrollment to 30 days, 3 months, 8 months, 12 months, 18 months, and 2 years of follow-up. For patients with ICA or MCA M1 segment occlusion, cognitive function assessment is performed at baseline and all follow-up time points. Subgroup analysis will be performed according to angiographic classification, stump morphology, duration from occlusion and clot characteristics. The study aims to recruit 160 patients in the ER plus SMT group and 320 patients in the SMT alone group (1:2 allocation).",,,,DetailedDescription,protocolSection.descriptionModule.detailedDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.conditions,TP,FP,['Intracranial Artery Occlusion With Infarction'],"['Intracranial Artery Occlusion', 'Stroke', 'Ischemic Stroke', 'Cerebrovascular Disease']",False,0.0,disjoint,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.keywords,TP,TP,"['standard medical therapy', 'symptomatic non-acute intracranial artery occlusion', 'endovascular recanalization']","['symptomatic non-acute intracranial artery occlusion', 'sNA-ICAO', 'endovascular recanalization', 'standard medical therapy', 'stroke', 'ischemic events', 'intracranial artery occlusion', 'cerebrovascular disease', 'antiplatelet therapy', 'stenting', 'balloon angioplasty']",True,1.0,superset,Keyword,protocolSection.conditionsModule.keywords,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.studyType,FN,FN,INTERVENTIONAL,,False,0.0,,StudyType,protocolSection.designModule.studyType,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.phases,FN,FN,['EARLY_PHASE1'],,False,0.0,,Phase,protocolSection.designModule.phases,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.allocation,FN,FN,NON_RANDOMIZED,,False,0.0,,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModel,FN,FN,PARALLEL,,False,0.0,,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.masking,FN,FN,SINGLE,,False,0.0,,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.whoMasked,FN,FN,['INVESTIGATOR'],,False,0.0,,DesignWhoMasked,protocolSection.designModule.designInfo.maskingInfo.whoMasked,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.enrollmentInfo.count,FN,FN,453,,False,0.0,,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[1].type,EV,EV,,DRUG,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].type,EV,EV,,DRUG,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].type,EV,EV,,DRUG,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[4].type,EV,EV,,DRUG,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[5].type,EV,EV,,BEHAVIORAL,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[6].type,EV,EV,,OTHER,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[7].type,EV,EV,,OTHER,,,,InterventionType,protocolSection.armsInterventionsModule.interventions.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[1].name,EV,EV,,Aspirin,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].name,EV,EV,,Clopidogrel,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].name,EV,EV,,Atorvastatin,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[4].name,EV,EV,,Heparin,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[5].name,EV,EV,,Lifestyle Modification Program (INTERVENT),,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[6].name,EV,EV,,Blood Pressure Control,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[7].name,EV,EV,,LDL Cholesterol Control,,,,InterventionName,protocolSection.armsInterventionsModule.interventions.name,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[1].description,EV,EV,,"100 mg/day as part of dual antiplatelet therapy for 90 days (SMT group) or 3-6 months (ER plus SMT group) followed by lifelong monotherapy. In ER plus SMT group, started at least 3 days before procedure.",,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].description,EV,EV,,"75 mg/day as part of dual antiplatelet therapy for 90 days (SMT group) or 3-6 months (ER plus SMT group) followed by lifelong monotherapy. In ER plus SMT group, started at least 3 days before procedure.",,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].description,EV,EV,,Used to control LDL cholesterol below 70 mg/dl in both treatment groups.,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[4].description,EV,EV,,"Given intravenously during endovascular procedure to maintain coagulation time between 200 and 300 seconds. After procedure, intravenous anticoagulation continued for at least 24-48 hours if no hemorrhagic complications.",,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[5].description,EV,EV,,"Lifestyle modification program provided to patients for management of secondary risk factors including diabetes, non-HDL cholesterol, smoking, weight and physical activity.",,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[6].description,EV,EV,,Systolic blood pressure controlled below 140 mmHg or 130 mmHg in patients with diabetes. Blood pressure tested at each follow-up visit and medication adjusted if standard not met.,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[7].description,EV,EV,,LDL cholesterol controlled below 70 mg/dl with Atorvastatin. LDL tested at each follow-up visit and medication adjusted if standard not met.,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[1].armGroupLabels,EV,EV,,"['Endovascular Recanalization plus Standard Medical Therapy (ER plus SMT)', 'Standard Medical Therapy Alone (SMT)']",,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[2].armGroupLabels,EV,EV,,"['Endovascular Recanalization plus Standard Medical Therapy (ER plus SMT)', 'Standard Medical Therapy Alone (SMT)']",,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[3].armGroupLabels,EV,EV,,"['Endovascular Recanalization plus Standard Medical Therapy (ER plus SMT)', 'Standard Medical Therapy Alone (SMT)']",,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[4].armGroupLabels,EV,EV,,['Endovascular Recanalization plus Standard Medical Therapy (ER plus SMT)'],,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[5].armGroupLabels,EV,EV,,"['Endovascular Recanalization plus Standard Medical Therapy (ER plus SMT)', 'Standard Medical Therapy Alone (SMT)']",,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[6].armGroupLabels,EV,EV,,"['Endovascular Recanalization plus Standard Medical Therapy (ER plus SMT)', 'Standard Medical Therapy Alone (SMT)']",,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.armsInterventionsModule.interventions[7].armGroupLabels,EV,EV,,"['Endovascular Recanalization plus Standard Medical Therapy (ER plus SMT)', 'Standard Medical Therapy Alone (SMT)']",,,,InterventionArmGroupLabel,protocolSection.armsInterventionsModule.interventions.armGroupLabels,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[3].measure,EV,EV,,Cognitive function,,,,SecondaryOutcomeMeasure,protocolSection.outcomesModule.secondaryOutcomes.measure,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[3].description,EV,EV,,"Assessment consists of five tests covering four domains: word list learning test and delayed recall test from Chinese version of ADAS-Cog, executive function/processing speed (animal naming and letter fluency), and attention/working memory (digit span). Assessed for patients with ICA or MCA M1 segment occlusion (anterior circulation)",,,,SecondaryOutcomeDescription,protocolSection.outcomesModule.secondaryOutcomes.description,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.secondaryOutcomes[3].timeFrame,EV,EV,,"From enrollment to 30 days, 3 months, 8 months, 12 months, 18 months, and 2 years of follow-up",,,,SecondaryOutcomeTimeFrame,protocolSection.outcomesModule.secondaryOutcomes.timeFrame,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"inclusion criteria:

1. Patient age ≥ 18 years old and life expectancy of 5 years or more.
2. Symptomatic sNA-ICAO defined as:diagnosed by CTA or MRA and confirmed by angiography; Vascular occlusion time more than 24 hours;TIA or ischemic stroke (confirmed by CT or MRI) related to the LCAO despite SMT \< 90 days prior to enrollment.
3. Modified Rankin scale score 0-2 at the time of informed consent.
4. More than one risk factor for atherosclerosis.
5. For patients with ICA or MCA M1 segment occlusion, ipsilateral hypoperfusion confirmed by CTP or MRI perfusion imaging prior to enrollment and analysis by the RAPID system.
6. For patients with intracranial segment occlusion of the vertebral artery, severe stenosis or occlusion of the contralateral vertebral artery.
7. Among women, no childbearing potential; or if a woman with childbearing potential, a negative pregnancy test result prior to randomization.
8. Agreement of the patient to comply with all protocol-specified follow-up appointments.
9. Signature by a patient of a consent form that has been approved by the local governing institutional review board (IRB)/medical ethics committee (MEC) of the respective clinical site.

exclusion criteria:

1. Intolerance or allergic reaction to a study medication without a suitable management alternative.
2. No atherosclerotic intracranial vasculopathies, such as dissection, moyamoya disease and vasculitis.
3. Concomitant intracranial aneurysms or any bleeding disorder.
4. Life expectancy \<1 year due to other medical conditions.
5. Large infarction core, defined as an ASPECTS \< 6 in anterior circulation and pc-ASPECTS \< 6 points in posterior circulation.
6. For patients with MCA M1 segment occlusion, concomitant ≥50% stenosis of the proximal internal carotid artery or other intracranial arteries.
7. For patients with intracranial segment occlusion of the vertebral artery, continuance of the occluded vertebral artery to the posterior inferior cerebellar artery with no stump.
8. Incomplete clinical and imaging data.
9. Coexistent cardioembolic source (e.g., atrial fibrillation, mitral stenosis, prosthetic valve, MI within six weeks, intracardiac clot, ventricular aneurysm and bacterial endocarditis).
10. Occlusive lesions with severe calcification.
11. Platelet count \<100,000/ml or history of heparin-induced thrombocytopenia.
12. Left ventricular ejection fraction \<30% or admission for heart failure in the prior 6 months.
13. Extreme morbid obesity that would compromise patient safety during the procedure or the periprocedural period.
14. Coronary artery disease with two or more proximal or major diseased coronary arteries with 70% stenosis that have not or cannot be revascularized.
15. Anticoagulation with Marcumar, warfarin or direct thrombin inhibitors or anti-XA drugs.
16. Chronic atrial fibrillation.
17. Any history of atrial fibrillation or paroxysmal atrial fibrillation in the past 6 months that is considered to require long-term anticoagulant therapy.
18. Other high-risk cardiogenic embolisms, including left ventricular aneurysm, severe cardiomyopathy, aortic or mitral mechanical heart valve, severe calcified aortic stenosis (valve area \< 1.0 cm2), endocarditis, moderate to severe mitral stenosis, left atrial thrombus or any intracardiac mass or known paradoxical embolism of unrepaired PFO.
19. Unstable angina defined as rest angina with ECG changes that is not amenable to revascularization (patients should undergo planned coronary revascularization at least 30 days before randomization).
20. Any major surgery, major trauma, revascularization procedure or acute coronary syndrome within the past 1 month.
21. serum creatinine \>2.5 mg/dl or estimated GFR \<30 cc/min.
22. Major surgery planned within 3 months after enrollment.
23. Currently listed or being evaluated for major organ transplantation (i.e., heart, lung, liver and kidney).
24. Participation in other trials and may affect the results of this study.
25. Inability to understand and cooperate with research procedures or provide informed consent.
26. Endarterectomy, bypass or stent implantation performed on the proximal end of the occlusion vessel.","Inclusion Criteria:
- Patients with imaging (MRA/CTA/DSA) and clinical diagnosis of symptomatic non-acute intracranial artery occlusion (sNA-ICAO)
- Occlusion occurring within 24 hours to 6 months
- For patients with ICA or MCA M1 segment occlusion, ipsilateral hypoperfusion should be confirmed by CTP or MRI perfusion imaging
- All patients gave written informed consent to participate

Exclusion Criteria:
- Unable or unwilling to provide written informed consent
- Contraindications to antiplatelet therapy or anticoagulation
- Hemorrhagic complications on head CT scan
- Life expectancy less than 2 years
- Unable to comply with follow-up schedule

Note: Specific inclusion and exclusion criteria are referenced in Tables 1 and 2 of the original document but detailed criteria are not fully specified in the provided text.",True,0.78,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,False,False,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.sex,TP,TP,ALL,ALL,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.minimumAge,TP,FP,18 Years,N/A,False,0.05,success,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.maximumAge,EV,EV,,N/A,,,,MaximumAge,protocolSection.eligibilityModule.maximumAge,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.stdAges,TP,TP,"['ADULT', 'OLDER_ADULT']","['ADULT', 'OLDER_ADULT']",True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.studyPopulation,EV,EV,,"Consecutive patients presenting with symptomatic non-acute intracranial artery occlusion (sNA-ICAO) at 15 centers in China between January 1, 2020 and December 31, 2022. Patients will be enrolled in either a cohort receiving standard medical therapy (SMT) alone or a cohort receiving endovascular recanalization (ER) plus SMT based on previous history, imaging features, and patient/family preferences.",,,,StudyPopulation,protocolSection.eligibilityModule.studyPopulation,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.samplingMethod,EV,EV,,NON_PROBABILITY_SAMPLE,,,,SamplingMethod,protocolSection.eligibilityModule.samplingMethod,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameter.designModule.designInfo.allocation,FP,FP,,NON_RANDOMIZED,False,0.0,,,protocolSection.designModule.parameter.designModule.designInfo.allocation,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameter.designModule.designInfo.maskingInfo.masking,FP,FP,,SINGLE,False,0.0,,,protocolSection.designModule.parameter.designModule.designInfo.maskingInfo.masking,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameter.designModule.designInfo.maskingInfo.maskingDescription,FP,FP,,Outcome will be determined by an adjudication committee that is unaware of the trial design and grouping.,False,0.0,,,protocolSection.designModule.parameter.designModule.designInfo.maskingInfo.maskingDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameter.designModule.designInfo.maskingInfo.whoMasked,FP,FP,,['OUTCOMES_ASSESSOR'],False,0.0,,,protocolSection.designModule.parameter.designModule.designInfo.maskingInfo.whoMasked,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameter.designModule.designInfo.observationalModel,FP,FP,,COHORT,False,0.0,,,protocolSection.designModule.parameter.designModule.designInfo.observationalModel,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameter.designModule.designInfo.timePerspective,FP,FP,,PROSPECTIVE,False,0.0,,,protocolSection.designModule.parameter.designModule.designInfo.timePerspective,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameter.designModule.enrollmentInfo.count,FP,FP,,480,False,0.0,,,protocolSection.designModule.parameter.designModule.enrollmentInfo.count,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameter.designModule.enrollmentInfo.type,FP,FP,,ESTIMATED,False,0.0,,,protocolSection.designModule.parameter.designModule.enrollmentInfo.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameter.designModule.patientRegistry,FP,FP,,True,False,0.0,,,protocolSection.designModule.parameter.designModule.patientRegistry,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameter.designModule.phases,FP,FP,,['NA'],False,0.0,,,protocolSection.designModule.parameter.designModule.phases,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameter.designModule.studyType,FP,FP,,OBSERVATIONAL,False,0.0,,,protocolSection.designModule.parameter.designModule.studyType,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameter.designModule.targetDuration,FP,FP,,2 years,False,0.0,,,protocolSection.designModule.parameter.designModule.targetDuration,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.parameter.identificationModule.briefTitle,FP,FP,,Endovascular Recanalization for Symptomatic Non-acute Intracranial Artery Occlusion,False,0.0,,,protocolSection.identificationModule.parameter.identificationModule.briefTitle,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.parameter.identificationModule.nctId,FP,FP,,NCT04864691,False,0.0,,,protocolSection.identificationModule.parameter.identificationModule.nctId,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.parameter.identificationModule.officialTitle,FP,FP,,"A Multisite, Non-randomized Cohort, Prospective Registry Study to Evaluate the Technical Feasibility and Safety of Endovascular Recanalization for Symptomatic Non-acute Intracranial Artery Occlusion",False,0.0,,,protocolSection.identificationModule.parameter.identificationModule.officialTitle,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.parameter.identificationModule.orgStudyIdInfo.id,FP,FP,,KY2020-114-02,False,0.0,,,protocolSection.identificationModule.parameter.identificationModule.orgStudyIdInfo.id,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.parameter.identificationModule.organization.class,FP,FP,,OTHER,False,0.0,,,protocolSection.identificationModule.parameter.identificationModule.organization.class,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.parameter.identificationModule.organization.fullName,FP,FP,,"Beijing Tiantan Hospital, Capital Medical University",False,0.0,,,protocolSection.identificationModule.parameter.identificationModule.organization.fullName,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.parameter.identificationModule.secondaryIdInfos,FP,FP,,"[{'id': '2018AAA0102600', 'type': 'OTHER_GRANT', 'domain': 'National Key R&D Program'}]",False,0.0,,,protocolSection.identificationModule.parameter.identificationModule.secondaryIdInfos,True,False,True,False,False,False
